Great Lakes Advisors LLC reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 56,933 shares of the biopharmaceutical company’s stock after selling 5,451 shares during the period. Great Lakes Advisors LLC’s holdings in Gilead Sciences were worth $3,867,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Hall Laurie J Trustee increased its position in shares of Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 250 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its position in shares of Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 1,400 shares in the last quarter. Dubuque Bank & Trust Co. increased its position in shares of Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 267 shares in the last quarter. Penserra Capital Management LLC increased its position in shares of Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 144 shares in the last quarter. Finally, Webster Bank N. A. increased its position in shares of Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 624 shares in the last quarter. Hedge funds and other institutional investors own 74.04% of the company’s stock.

Gilead Sciences, Inc. (GILD) traded up 2.82% during trading on Monday, hitting $75.87. The stock had a trading volume of 9,675,647 shares. The company has a 50-day moving average of $72.97 and a 200-day moving average of $68.86. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $82.07. The stock has a market capitalization of $99.08 billion, a P/E ratio of 8.24 and a beta of 1.21.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.11 by $0.45. The firm had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business’s revenue was down 8.2% compared to the same quarter last year. During the same period in the prior year, the company earned $3.08 EPS. On average, equities analysts expect that Gilead Sciences, Inc. will post $8.74 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.82%. The ex-dividend date is Thursday, September 14th. Gilead Sciences’s dividend payout ratio is 22.58%.

COPYRIGHT VIOLATION WARNING: “Great Lakes Advisors LLC Has $3.87 Million Position in Gilead Sciences, Inc. (GILD)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/08/28/great-lakes-advisors-llc-has-3-87-million-position-in-gilead-sciences-inc-gild.html.

Several research analysts have recently commented on the company. Jefferies Group LLC reiterated a “hold” rating and set a $80.00 target price on shares of Gilead Sciences in a research note on Tuesday, July 11th. Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a research note on Monday. Vetr downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $82.15 target price for the company. in a research note on Monday. BMO Capital Markets reiterated a “hold” rating and set a $76.00 target price (up from $75.00) on shares of Gilead Sciences in a research note on Wednesday, May 3rd. Finally, Barclays PLC reiterated an “overweight” rating and set a $85.00 target price on shares of Gilead Sciences in a research note on Wednesday, May 3rd. Eleven analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. Gilead Sciences currently has a consensus rating of “Buy” and a consensus target price of $80.58.

In other news, EVP Gregg H. Alton sold 5,000 shares of the company’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.06, for a total transaction of $355,300.00. Following the sale, the executive vice president now directly owns 102,988 shares in the company, valued at approximately $7,318,327.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gregg H. Alton sold 40,000 shares of the company’s stock in a transaction dated Friday, July 21st. The shares were sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the sale, the executive vice president now owns 137,488 shares in the company, valued at $10,174,112. The disclosure for this sale can be found here. Insiders have sold a total of 206,666 shares of company stock worth $15,223,184 over the last 90 days. Corporate insiders own 1.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.